AZD3965 is an inhibitor of the monocarboxylate (lactate) transporter MCT1 (SLC16A1) [2
]. Eklevated MCT1 expression has been reported in a range of solid tumours [4
] and it is functionally essential in certain lymphomas which are highly dependent on the glycolytic metabolic pathway [3
]. It appears that cancer cells exploit MCT1 to efflux lactate so as to prevent intracellular acidification so as to prevent metabolic catastrophe. MCT1 inhibitors are being investigated for their potential to inhibit glycolysis and tumour growth.